RecruitingPhase 2NCT07073365

Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)

A Prospective Cohort Observational Study of Local Therapy for the Primary Tumor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer Following Osimertinib Plus Chemotherapy (FLAURA2 Regimen)

Sponsor

Pusan National University Hospital

Enrollment

70 participants

Start Date

Jul 1, 2025

Study Type

INTERVENTIONAL

Conditions

Non-small Cell Lung Cancer Epidermal Growth Factor Receptor

Summary

This is a single-arm, open-label, phase II study evaluating the clinical outcomes of local therapy (surgery or radiotherapy) to the primary tumor in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) who have achieved disease control following first-line treatment with the FLAURA2 regimen (osimertinib plus platinum-based chemotherapy). The primary objective is to assess the median progression-free survival (PFS) after local therapy.

Eligibility

Min Age: 20 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at whether adding targeted treatment to the primary lung tumor (through surgery or radiation) helps people with advanced lung cancer who responded well to initial chemotherapy and a targeted drug called osimertinib. **You may be eligible if...** - You are 20 years or older - You have been diagnosed with non-small cell lung cancer (NSCLC) that has spread (Stage IV) - Your tumor has a specific gene change called an EGFR mutation (exon 19 deletion or L858R) - You have completed 4 cycles of osimertinib plus platinum-based chemotherapy - Your cancer showed some response or was stable after that treatment - You still have a remaining tumor in your lung that could be treated with surgery or radiation - You are in good overall health (able to carry out daily activities) **You may NOT be eligible if...** - Your cancer got worse during initial chemotherapy - You have unstable or untreated brain metastases - You have another active cancer requiring treatment - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERLocal Therapy (Surgery or Radiotherapy)

Patients will receive local therapy, either surgical resection or radiotherapy, to the primary lung tumor following disease control after first-line treatment with osimertinib plus platinum-based chemotherapy (FLAURA2 regimen). The specific modality (surgery or radiotherapy) will be determined based on tumor characteristics, patient condition, and multidisciplinary team assessment.